134 related articles for article (PubMed ID: 31621100)
1. Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.
Williams AM; Baran AM; Schaffer M; Bushart J; Rich L; Moore J; Barr PM; Zent CS
Am J Hematol; 2020 Jan; 95(1):E16-E18. PubMed ID: 31621100
[No Abstract] [Full Text] [Related]
2. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
Innocenti I; Morelli F; Autore F; Corbingi A; Pasquale R; Sorà F; Pompili M; Laurenti L
Leuk Lymphoma; 2019 May; 60(5):1340-1342. PubMed ID: 30730231
[No Abstract] [Full Text] [Related]
3. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
[No Abstract] [Full Text] [Related]
4. Is HBV prophylaxis required during CLL treatment with ibrutinib?
Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M
Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112
[No Abstract] [Full Text] [Related]
5. Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
Ball S; Vutthikraivit W; Maiti A; Short NJ
Eur J Haematol; 2018 Sep; 101(3):418-420. PubMed ID: 29791043
[No Abstract] [Full Text] [Related]
6. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
Saenz-de-Viteri M; Cudrnak T
Leuk Lymphoma; 2019 Mar; 60(3):842-844. PubMed ID: 30188238
[No Abstract] [Full Text] [Related]
7. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
Kreiniz N; Bejar J; Polliack A; Tadmor T
Hematol Oncol; 2018 Feb; 36(1):349-354. PubMed ID: 28156016
[TBL] [Abstract][Full Text] [Related]
8. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
Goldschmidt N; Rund D
Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
[No Abstract] [Full Text] [Related]
9. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
Sato R; Jacob J; Gaballa S
Leuk Lymphoma; 2018 Jul; 59(7):1738-1741. PubMed ID: 29081253
[No Abstract] [Full Text] [Related]
10. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
Thompson PA; Lévy V; Tam CS; Al Nawakil C; Goudot FX; Quinquenel A; Ysebaert L; Michallet AS; Dilhuydy MS; Van Den Neste E; Dupuis J; Keating MJ; Meune C; Cymbalista F
Br J Haematol; 2016 Nov; 175(3):462-466. PubMed ID: 27611233
[TBL] [Abstract][Full Text] [Related]
11. Probable Invasive Pulmonary Cryptococcosis and Possible Cryptococcal Empyema in CLL Treated With Frontline Ibrutinib.
Koehler AB; Vijayvargiya P; Ding W
Mayo Clin Proc; 2019 May; 94(5):915-917. PubMed ID: 31054610
[No Abstract] [Full Text] [Related]
12. Resolution of eosinophilia and elevated immunoglobulin E with ibrutinib for chronic lymphocytic leukemia.
Harada K; Brooks JP; Lobo FM
Ann Allergy Asthma Immunol; 2018 Nov; 121(5):629-630.e1. PubMed ID: 30009879
[No Abstract] [Full Text] [Related]
13. How I treat CLL patients with ibrutinib.
Brown JR
Blood; 2018 Jan; 131(4):379-386. PubMed ID: 29255067
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
Ambinder AJ; Hambley B; Shanbhag S; Merrill SA
Am J Hematol; 2019 Nov; 94(11):E296-E299. PubMed ID: 31400009
[No Abstract] [Full Text] [Related]
15. Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL).
Wright N; Voshtina E; George G; Singavi A; Field J
Int J Hematol; 2019 Dec; 110(6):751-755. PubMed ID: 31494832
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ryan CE; Sahaf B; Logan AC; O'Brien S; Byrd JC; Hillmen P; Brown JR; Dyer MJ; Mato AR; Keating MJ; Jaglowski S; Clow F; Rezvani AR; Styles L; Coutre SE; Miklos DB
Blood; 2016 Dec; 128(25):2899-2908. PubMed ID: 27802969
[TBL] [Abstract][Full Text] [Related]
17. FDA grants accelerated approval for ibrutinib for CLL.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E10. PubMed ID: 25618623
[No Abstract] [Full Text] [Related]
18. Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.
Poole A; Girard N; Clayton F; Tantravahi SK
Leuk Lymphoma; 2017 May; 58(5):1258-1261. PubMed ID: 27750463
[No Abstract] [Full Text] [Related]
19. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
Molica S; Levato L; Mirabelli R
Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
[No Abstract] [Full Text] [Related]
20. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Molica S
Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]